Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845003 | 0.86 | ALDH1A1 (0.40) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL7769437 | 0.86 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AALOX12 | |
| SCHEMBL19911199 | 0.78 | NSD2 (0.40) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL13404895 | 0.77 | MGLL (0.37) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL22833046 | 0.76 | KDM4E (0.54) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL10076741 | 0.74 | L3MBTL1 (0.45) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL12092089 | 0.74 | L3MBTL1 (0.54) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL16053638 | 0.73 | ACP1 (0.44) | MEN1KMT2AMAPTCYP3A4 | |
| SCHEMBL17747110 | 0.72 | CA12 (0.46) | ALDH1A1HPGDMEN1KMT2AL3MBTL1 | |
| SCHEMBL2590087 | 0.72 | NOTUM (0.36) | ALDH1A1HPGDKMT2AALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393745-A1 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE | NOVO NORDISK A/S (DK) | 2021-12-23 | — | — | US | claimed |
| EP-3863680-A1 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE | Novo Nordisk A/S (DK) | 2021-08-18 | — | — | EP | claimed |
| CN-112839681-A | Oligomer-extended insulin-Fc conjugates and medical uses thereof | 诺和诺德股份有限公司 | 2021-05-25 | — | — | CN | claimed |
| EP-4700044-A1 | PROTEIN ANALOGUE AND USE THEREOF | Shanghai Duomirui Biotechnology., Ltd. (CN) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024199481-A1 | PROTEIN ANALOGUE AND USE THEREOF | 上海多米瑞生物技术有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | NOVO NORDISK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20210393745-A1 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE | NOVO NORDISK A/S (DK) | 2021-12-23 | — | — | US | disclosed |
| US-20210393745-A1 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE | NOVO NORDISK A/S (DK) | 2021-12-23 | — | — | US | disclosed |
| EP-3863680-A1 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE | Novo Nordisk A/S (DK) | 2021-08-18 | — | — | EP | disclosed |
| CN-112839681-A | Oligomer-extended insulin-Fc conjugates and medical uses thereof | 诺和诺德股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| EP-3606560-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | Novo Nordisk A/S (DK) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185131-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | NOVO NORDISK A/S (DK) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | IAPP, IDE, INSR | ALDH1A1 4710/4885HPGD 4347/4885MEN1 381/4885 |
| US-20210393745-A1 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE | IAPP, IDE, INSR | ALDH1A1 4730/4885HPGD 4265/4885MEN1 375/4885 |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | IAPP, IDE, INSR | ALDH1A1 4710/4885HPGD 4347/4885MEN1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.